Lightnews — Scholar-powered news

Kathy D Miller, MD @kathydmillermd.bsky.social · Aug 10

Unfortunately the study design doesn’t allow us to evaluate clinical utility of the early switch
Clearly an active drug… but this isn’t the way to use it

1 1

Kathy D Miller, MD @kathydmillermd.bsky.social · Jun 6

Still seats on the Pacer’s bandwagon if you’d like to jump on😀⛹🏻‍♂️

1

Kathy D Miller, MD @kathydmillermd.bsky.social · Jun 5

Nora
When you account for lead time bias, it’s not clear this is even a single

Reposted by Kathy D Miller, MD

MidwestHedonist @midwesthedonist.bsky.social · Jun 3

Spread the love and acceptance #pridemonth

370 15K 20K

Kathy D Miller, MD @kathydmillermd.bsky.social · Jun 2

Great time with early career attendees today at the JCO poster walk this morning
The future of our field is indeed bright

2

Kathy D Miller, MD @kathydmillermd.bsky.social · Jun 1

Clearly an active drug but this may not be the best way to use it or to really benefit patients
Discussant Dr DeMichele did a great job explaining the problems with study design and interpretation

1

Kathy D Miller, MD @kathydmillermd.bsky.social · Jun 1

Serena 6 AI PFS 9.2 mos + 6.3 mos (PFS 2nd line cami)= 15.5
Sounds like the 16 mos with early switch?
I know…. Cross trial comparisons are hard but lead time bias is real

1

Kathy D Miller, MD @kathydmillermd.bsky.social · Jun 1

Have to ask how Serena 6 got into NEJM?
PFS2 as defined is really PFS2 in control arm vs PFS3 in cami arm
Uninterpretable and real potential that pts will move to chemo sooner than needed

1

Kathy D Miller, MD @kathydmillermd.bsky.social · May 31

My new favorite assessment
The SMOG readability score
SMOG = simple measure of gobbledygook

Use it to determine the education level needed for comprehension

Kathy D Miller, MD @kathydmillermd.bsky.social · May 31

Shout out to Gilead and the Ascent 4 trial for providing an opportunity to crossover to pts randomized toTPC.
Finally respect for pts who agree to participate

Kathy D Miller, MD @kathydmillermd.bsky.social · May 31

Stop by JCO central while at ASCO. Enjoy the coffee, meet the editors and staff, learn more about JCO

1 2

Kathy D Miller, MD @kathydmillermd.bsky.social · May 18

Ithenticate works well

2

Kathy D Miller, MD @kathydmillermd.bsky.social · Mar 31

So thoughtful and personal… way better than the standard coffee mug😀

1 1

Kathy D Miller, MD @kathydmillermd.bsky.social · Mar 29

Welcome😀

1

Kathy D Miller, MD @kathydmillermd.bsky.social · Jan 19

So sorry Wendy. Wishing you both peace

2

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 13

Kudos to Dr Krop for. Great balanced discussion. MRD testing has great promise but also brings great potential for harm. Success of any MRD test is inextricably linked to success of our therapeutic interventions. We’re just not there yet.

Bottom line…don’t do it
#SABCS2024

1 2

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 13

Hard to get excited or see a future for atezo in breast

Neg results for EFS in GerparDouze, neg adjuvant Impassion 030, no benefit with paclitaxel in MBC

No spin here, time to move in and conclude pembro just makes gut be better in our disease
#SABCS2024

1 3

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 12

Important message lost here
Hormone inhibition is key if ER positive regardless oh HER2. Many HER2 focused trials exclude/ don’t allow ongoing hormone therapy. Cleopatra for example … if the tumor has both targets we shouldn’t have to choose

1 2

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 11

No questions allowed after the EMBER 3 presentation
How is endocrine therapy alone SOC for the 40 percent with no prior CDKi exposure?
When they amended to add illum plus abema arm they should have added SOC plus abema too
Without that control, the data are impossible to interpret

4

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 10

No doubt ctDNA informs risk estimates. What we need and still lack is data on outcomes
Specifically do patients live longer if managed with knowledge of the test than without

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 10

No question ctDNA can inform estimates of risk
What we lack and need is data on patient outcomes
Specifically do patients live longer if management decisions are made with knowledge of the test versus not

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 10

Amazing progress powered by basic science and spurred by advocates who demanded better access and engagement

Still remember my time on Osler 8, the aids unit at JHU back in the day

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 9

Don
I had read and admired the piece
I was reflecting on the experiences of two recent trans patients, each seen in one of my two clinic locations
One visit started with a patient in tears from the limited options the intake form provided
Sorry my comment didn’t include enough words

1

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 9

Personally I have always hated both. We all have things to learn and things we can teach

2

Kathy D Miller, MD @kathydmillermd.bsky.social · Dec 9

Great practical advice in this piece? When’s the last time you looked at patient intake forms with an eye toward diversity and inclusion?